Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.

* denotes publications from the CTD2 initiative that are results of intra-Network collaborations


March 29, 2018
Clinical Cancer Research

Fred Hutchinson CTD2 researchers identified novel therapeutic targets for precision oncology using high-throughput functional phenotyping with siRNA and drug libraries in primary patient derived head and neck cancer cells.

March 13, 2018
Clinical Cancer Research

CTD2 scientists at Fred Hutchinson showed that the triplet combination of WEE1 tyrosine kinase inhibitor AZD1775, cisplatin, and docetaxel is safe, tolerable, and effective in a phase I clinical trial of head and neck cancer.

March 06, 2018
Cancer Discovery

Scientists proposed a framework to investigate the genomic alterations in neuroblastoma subtypes and identified, TEAD4, a transcription factor as a novel target for therapy.

March 01, 2018
ASSAY and Drug Development Technologies

CTD2 scientists at Emory University developed a high-throughput time-resolved fluorescence resonance energy transfer assay to discover small-molecule inhibitors of receptor binding protein, NSD3 protein-protein interactions.

February 28, 2018

TARGET researchers analysed DNA changes and sequenced the genomes, exomes, and transcriptomes of 1,699 pediatric leukemia and solid tumors. They identified 142 genes associated with cancer in these pediatric patients, of which only 45% matched those found in similar studies of adult cancers.

February 22, 2018
Nat Commun

CSHL CTD2 scientists developed a method that allows temporal control of CRISPR/Cas9 by conjugating a destabilizing domain to Cas9. This robust high-throughput approach can be used for gene editing and to investigate interactions between functional genes.

February 16, 2018
ACS Chem Biol

Review of methods with a focus on chemical-genetic screens used in the identification of the mechanisms of action of small molecules.

February 13, 2018
Cell Reports

CTD2 scientists at UCSF (1) identified two major subtypes of KRAS mutant cancers of the lung, pancreas, and the large intestine which differentially engage effector pathways. These findings can be used to develop effective combination of therapies.

February 05, 2018
Cancer Res

Studies demonstrated that epithelial-to-mesenchymal transition-inducing transcription factor, Snail, represses tumor suppressive RNA splicing regulatory protein, ESRP1, and promotes tumorigenesis in lung cancer.